Biotech Values

[DewDiligence]

SYRS plans dissolution:

https://www.businesswire.com/news/home/20250228459350/en

…as previously disclosed, the Company’s SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine failed to meet its primary endpoint of complete response rate, which failure resulted in an event of default under the Company’s loan and security agreement with Oxford Finance, LLC… In light of these factors, the Board determined that it is in the Company's best interests that the Company take steps designed to preserve sufficient cash to fund an orderly wind down of the Company's operations and to maximize the Company's cash position for the benefit of its stakeholders.